Evotec receives € 3 million payment from Sanofi
Evotec achieves second milestone in diabetes alliance with Sanofi
This milestone was triggered after Evotec met pre-agreed critical success criteria for a potential manufacturing process for generation of human induced pluripotent stem cell (iPSC)-derived beta cells, including the demonstration of upscaling potential and suitability of the cell product for encapsulated beta cell function in diabetes models. The goal of the collaboration is to develop a beta cell replacement therapy based on beta cells derived from human iPS cells.
Dr Cord Dohrmann, Chief Scientific Officer of Evotec, commented: “Diabetes is one of the major threats to global healthcare with over 420 million people across the globe affected by either type 1 and type 2 diabetes. We are very pleased with the progress we are making towards a potential game changing beta cell therapy approach and remain committed to discover additional treatment options together with our colleagues at Sanofi.”
Most read news
Organizations
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.